Biogen Inc. (LON:0R1B)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 16.28B |
| Revenue (ttm) | 7.73B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.93 |
| PE Ratio | 12.49 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,667 |
| Average Volume | 6,628 |
| Open | 135.95 |
| Previous Close | 136.32 |
| Day's Range | 135.13 - 137.88 |
| 52-Week Range | 135.39 - 137.88 |
| Beta | -0.08 |
| RSI | 46.05 |
| Earnings Date | Feb 13, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of amyotrophic lateral sclerosis; FUMADERM for the treatment of plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMR... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
What key earnings releases are scheduled for the week starting Feb 10
With Amazon reporting after the close yesterday, the only Magnificent 7 name left to report is Nvidia. They won't announce earnings until February 26. Next week the earnings will be highlighted by the...
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
New On The Block Sage Therapeutics, Inc . NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination ...
Biogen, Eisai Alzheimer’s drug review delayed in EU
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
Biogen Inc (BIIB) Announces FDA Approval for Alzheimer's Treatment LEQEMBI
Biogen Inc (BIIB) Announces FDA Approval for Alzheimer's Treatment LEQEMBI
Biogen Inc (BIIB) Announces FDA Approval for New Alzheimer's Treatment Dosing
Biogen Inc (BIIB) Announces FDA Approval for New Alzheimer's Treatment Dosing
FDA Approves Biogen's LEQEMBI for Alzheimer's Maintenance Dosing
FDA Approves Biogen's LEQEMBI for Alzheimer's Maintenance Dosing
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with...
Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA Applications are based o...
Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth
The Genetic Toxicology Testing market is expected to rise due to rising genetic disease incidence, advancements in genetic toxicology testing technologies, increased R&D activities, strategic collabor...
Biogen partner Eisai reportedly sees FY25 launch for home version of Alzheimer’s drug
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE stock is a good buy at these levels.
Looking At Biogen's Recent Unusual Options Activity
Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ: BIIB) revealed 8 unusual trades. Delving into the details, we found 37% of traders...
Sage sues Biogen in wake of $469M buyout offer: report
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Analysis of Sage Therapeutics' financials and pipeline setbacks, including an unsolicited offer from Biogen, suggest a hold for investors. Click here to read.
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen CEO sees no burning need for more acquisitions
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.